2018 Q4 report, Period October-December

Period October-December

  • Net sales: kSEK 0 (0)
  • Operating profit: kSEK -2 184 (-854)
  • Earnings per share: SEK -0,10 (-0,06)
  • Liquidity at the end of the period: kSEK 306 (2 124)

Period January-December

  • Net sales: kSEK 0 (0)
  • Operating profit: kSEK -4 716 (-4 200)
  • Earnings per share: SEK -0,25 (-0,32)
  • Liquidity at the end of the period: kSEK 306 (2 124)

CEO statement
Panion's epilepsy project for dogs has taken some big steps forward and I want to start with thanking all our investors for their support and trust in our idea.

During the year, the new clinical safety study in dogs was finalized successfully at the University of Copenhagen, and the results have been released. It was encouraging to see that all the treated dogs were without observable adverse reactions. A few of the microscopic analyses of tissue and vector expression are still being worked on, and the final report is awaited from the researchers, but these last analyses are more of academic interest than of importance to Panion's project.

The pre-submission meeting with the US-FDA in Maryland/Washington DC was a major milestone achieved this year. Panion's gene therapy product against epilepsy was presented for authority reviewers from FDA. We had prepared and submitted a long document to the FDA including a list of questions that we wanted to get the reviewers feedback on. The answers will help us make the development plan as concrete as possible, including getting a firmer estimate of the development costs and timelines.

The most important milestone this year was the starting of the clinical pilot-study in privately owned dogs with drug-refractory epilepsy in a large veterinary clinic in New York. It is an impressive specialist veterinary clinic with full equipment and highly skilled staff, including veterinary neurosurgeons and neurologists. The study is officially started and the screening for patients to be enrolled ongoing. Each dog must first be screened over a number of weeks to document its type and frequency of epilepsy, before the treatment with Panion's gene therapy takes place, followed by the period of monitoring for efficacy, i.e. reduced epilepsy. We are overly excited to learn the first results of how the product works in real epileptic cases.

The information from the pilot-study will direct us towards the next step of a regulatory safety study and if the efficacy from the pilot study is good, these two studies may be sufficient to get a so-called conditional approval in USA. This would mean that we can start to sell the product, while we collect data for the pivotal regulatory clinical efficacy study, which is needed for a full approval.

The latest share emission in December 2018 was not very successful, and we must admit that it was probably a wrong timing for an emission just before Christmas. Other sources of financing are identified and pursued in the short horizon.

However, in February we have been invited to present Panion at a large investor forum in London, Animal Health Investment - Europe. Here all the large companies and many animal health investors are present and will hear about our plans and good development over the last 2 years. We hope that options and connections for good future cooperation will result from this meeting.

It is Panion's firm ambition to extend our product portfolio and we are investigating several options of potential in-licensing opportunities, to select promising candidates. We will continue to inform about the progress and development as early as possible. I encourage you to read more details about our business on the website.

Thank you very much for your interest.

Anja Holm, CEO, Panion Animal Health AB

Anja E. H. Holm, CEO
+ 45-22 94 66 00
anja.holm@panion-animalhealth.com 

Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.

Nerladdningsbara filer

Information avseende budet från CombiGene

Styrelsen i Panion Animal Health mottog den 18 april ett bud på Panion Animal Health från CombiGene. Budet löpte ut den 20 juni (-19).


Påminnelse angående budet från CombiGene

Styrelsen i Panion Animal Health mottog den 18 april ett bud på Panion Animal Health från CombiGene. Budet löper ut den 20 juni (-19).





2019 Q1 report, Period January-March for Panion Animal Health AB

Period January-March

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -1 663 (-697).
  • Earnings per share: SEK -0,07 (-0,05).
  • Liquidity at the end of the period: kSEK 4 961 (2 708).

Styrelsen för Panion Animal Health AB (publ) ("Panion" eller "Bolaget") rekommenderar enhälligt aktieägarna och teckningsoptionsinnehavarna i Panion att acceptera CombiGenes offentliga erbjudande

Styrelsen för Panion Animal Health AB (publ) ("Panion" eller "Bolaget") rekommenderar enhälligt aktieägarna och teckningsoptionsinnehavarna i Panion att acceptera CombiGenes offentliga erbjudande


Kommuniké från årsstämma i Panion Animal Health AB (publ)

Idag, den 23 april 2019, hölls årsstämma i Panion Animal Health AB. Nedan följer en sammanfattning av de beslut som fattades vid årsstämman.


CombiGene lämnar ett offentligt uppköpserbjudande till innehavarna av aktier och teckningsoptioner av serie TO1 i Panion Animal Health

CombiGene AB (publ) ("CombiGene") har idag lämnat ett offentligt uppköpserbjudande till innehavarna av aktier ("Aktierna) och teckningsoptioner av serie TO1 med ISIN-kod SE0011205343 ("Teckningsoptionerna") i Panion Animal Health AB (publ) ("Panion" eller "Bolaget") att överlåta samtliga sina Aktier och Teckningsoptioner till CombiGene ("Erbjudandet"). Aktierna och Teckningsoptionerna är upptagna till handel på Spotlight Stock Market ("Spotlight").



Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär